Who makes ONT-10, Varlilumab combination?

ONT-10, Varlilumab combination is developed by Cascadian Therapeutics Inc..

What development phase is ONT-10, Varlilumab combination in?

ONT-10, Varlilumab combination is in Phase 1.

Last reviewed 2026-05-15 · How we verify

ONT-10, Varlilumab combination

Cascadian Therapeutics Inc. · Phase 1 active Biologic

At a glance

Generic name	ONT-10, Varlilumab combination
Sponsor	Cascadian Therapeutics Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ONT-10, Varlilumab combination CI brief — competitive landscape report
ONT-10, Varlilumab combination updates RSS · CI watch RSS
Cascadian Therapeutics Inc. portfolio CI